GO
Loading...

Cramer: Gilead crux of health care in US

Wednesday, 23 Apr 2014 | 9:08 AM ET

Record sales of a new hepatitis C drug pushed the first-quarter earnings of Gilead Sciences beyond expectations. The "Squawk on the Street" news team break down its quarterly beat.